ClinicalTrials.gg

Program

calderasib

Also written as “Calderasib”, “MK-1084” and “[14C]Calderasib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Colonic Neoplasms · Renal Insufficiency, led by Merck.

Furthest: phase 3, since Mar 28, 202412 company-led studies, 8 open or runningNext primary completion: Jan 24, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck128 open or runningphase 3since Mar 28, 2024Oct 1, 2021Jan 24, 2028phase 3 · NCT06345729
  • Named in Merck’s own pipeline as calderasib (MK-1084), phase 3, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 1, 2021First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05067283 · 830 planned · United States, Argentina, Australia and more
  2. Mar 28, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06345729 · 348 planned · United States, Argentina, Australia and more
  3. Sep 26, 2024Phase 1 study in HealthyNCT06619314 · 56 enrolled · United States
  4. Nov 12, 2024Phase 1 study in HealthyNCT06687759 · 8 enrolled · United States
  5. Feb 3, 2025Phase 1 study in Renal InsufficiencyNCT06814119 · 34 enrolled · United States
  6. May 21, 2025Phase 3 study in Colonic NeoplasmsNCT06997497 · 477 planned · United States, Argentina, Australia and more
  7. Sep 16, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07190248 · 675 planned · United States, Argentina, Australia and more
  8. Sep 30, 2025Phase 2 study in NeoplasmsNCT07209111 · 150 planned · United States, Australia, Canada and more
  9. Oct 20, 2025Phase 1 study in HealthyNCT07219550 · 32 enrolled · United States
  10. Nov 20, 2025Phase 2 study in NeoplasmsNCT07252739 · 140 planned · United States, Chile, China and more
  11. Feb 19, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07431827 · 400 planned · Argentina, Australia, Brazil and more
  12. Apr 21, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07554339 · 310 planned · United States, Argentina, Australia and more

Ahead

  1. Jan 24, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06345729
  2. Mar 28, 2029Primary completion: phase 3 study in Colonic NeoplasmsNCT06997497
  3. Nov 15, 2029Primary completion: phase 2 study in NeoplasmsNCT07252739
  4. Dec 7, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07190248

TargetBeta

“An orally available inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, calderasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C-mediated signaling. This may halt proliferation and metastasis in susceptibl…”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07554339Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingDec 15, 2032310
NCT07431827Carcinoma, Non-Small-Cell Lung · Argentina, Australia, Brazil and more3RecruitingOct 26, 2039400
NCT07252739Neoplasms · United States, Chile, China and more2RecruitingNov 15, 2029140
NCT07219550Healthy · United States1CompletedJul 15, 202632
NCT07209111Neoplasms · United States, Australia, Canada and more2RecruitingApr 9, 2032150
NCT07190248Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingDec 7, 2029675
NCT06997497Colonic Neoplasms · United States, Argentina, Australia and more3RecruitingMar 28, 2029477
NCT06814119Renal Insufficiency · United States1CompletedJan 23, 202634
NCT06687759Healthy · United States1CompletedAug 7, 20248
NCT06619314Healthy · United States1CompletedNov 25, 202356
NCT06345729Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingJan 24, 2028348
NCT05067283Advanced Solid Tumors · United States, Argentina, Australia and more1RecruitingFeb 25, 2030830

How it is read

Names in the registry

  • “Calderasib”, 10 entries
  • “MK-1084”, 1 entry
  • “[14C]Calderasib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.